GlassScriptPhysician profile
Carol Ann Bogdan
NPI 1033102538
$2,803.11
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $654 · 2021: $386 · 2022: $649 · 2023: $320 · 2024: $14.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $726.99 | 2019-2023 | |
| Janssen Biotech, INC. | $199.15 | 2020-2023 | Imbruvica |
| Amgen INC. | $177.73 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Merck Sharp & Dohme LLC | $160.96 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $133.18 | 2019-2023 | Opdivo |
| Celgene Corporation | $127.77 | 2019-2023 | Reblozyl |
| Pfizer INC. | $119.64 | 2019-2023 | |
| Genentech USA, INC. | $117.89 | 2019-2022 | |
| Incyte Corporation | $105.53 | 2019-2022 | |
| Daiichi Sankyo INC. | $93.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $87.23 | 2019-2023 | Enhertu |
| Lilly USA, LLC | $77.48 | 2019-2020 | |
| Eisai INC. | $77.26 | 2019-2022 | |
| Glaxosmithkline, LLC. | $69.00 | 2020-2022 | |
| Gilead Sciences, INC. | $62.13 | 2019-2023 | Trodelvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $61.80 | 2021-2023 | Padcev |
| Ipsen Biopharmaceuticals, INC | $35.37 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $34.46 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $33.27 | 2020-2021 | |
| Kite Pharma, INC. | $30.73 | 2020-2021 | |
| Seagen INC. | $29.65 | 2021-2023 | Tukysa |
| Coherus Oncology, INC. | $28.64 | 2023 | |
| Morphosys, US INC. | $28.42 | 2021-2023 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.39 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.03 | 2022 | |
| Stemline Therapeutics INC. | $19.36 | 2023 | Orserdu |
| Genzyme Corporation | $18.62 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.51 | 2021 | |
| Puma Biotechnology, INC. | $16.40 | 2022 | |
| Myovant Sciences INC. | $16.22 | 2022 | |
| Array Biopharma INC | $14.93 | 2024 | Mektovi, Xalkori, Braftovi |
| Mirati Therapeutics, INC. | $14.44 | 2023 | Krazati |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Bogdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.